News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Agrees To Review Eli Lilly and Company (LLY)/Boehringer Ingelheim Corporation's Lantus Biosimilar


12/23/2013 7:26:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

US regulators have agreed to review Eli Lilly/Boehringer Ingelheim's long-acting insulin LY2963016, a biosimilar of Sanofi's blockbuster diabetes treatment Lantus (insulin glargine). The US Food and Drug Administration will assess the drug as a treatment for both type I and type II diabetes, following in the footsteps of regulators across the pond in Europe. Lilly and Boehringer say they have studied LY2963016 "in a comprehensive development programme in order to meet the regulatory standards of clinical and nonclinical safety, efficacy and quality," and note that the filing also contains data from Phase III trials in which their treatment was pitted against Lantus.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES